PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	40.88	37.71	108.3	172.47	361.42
Short-Term Investments	128.58	165.35	132.76	124.7	-
Cash & Short-Term Investments	169.45	203.06	241.05	297.16	361.42
Cash Growth	-16.55%	-15.76%	-18.88%	-17.78%	256.13%
Prepaid Expenses	6.2	3.53	5.13	3.3	3.34
Restricted Cash	-	0.82	0.82	0.82	-
Total Current Assets	175.66	207.41	247.01	301.29	364.76
Property, Plant & Equipment	1.55	19.05	20.49	13.15	0.57
Long-Term Investments	13.84	25.51	2.5	16.91	-
Other Long-Term Assets	0.24	0.19	0.31	0.22	0.2
Total Assets	191.29	252.15	270.31	331.57	365.53
Accounts Payable	6.58	3.24	3	3.19	1.61
Accrued Expenses	7.44	9.94	7.31	8.63	4.8
Current Portion of Leases	0.35	0.85	0.53	0.4	-
Total Current Liabilities	14.37	14.03	10.83	12.22	6.41
Long-Term Leases	0.84	12.43	13.45	10.79	-
Total Liabilities	15.21	26.46	24.28	23.01	6.41
Additional Paid-In Capital	544.65	535.47	487.52	476.36	469
Retained Earnings	-368.71	-310	-241.04	-167.73	-109.88
Comprehensive Income & Other	0.14	0.22	-0.45	-0.08	-
Total Common Equity	176.08	225.69	246.03	308.56	359.12
Shareholders' Equity	176.08	225.69	246.03	308.56	359.12
Total Liabilities & Equity	191.29	252.15	270.31	331.57	365.53
Total Debt	1.19	13.29	13.98	11.19	-
Net Cash (Debt)	182.11	215.28	229.57	302.88	361.42
Net Cash Growth	-15.41%	-6.23%	-24.20%	-16.20%	256.13%
Net Cash Per Share	3.53	4.48	5.04	6.71	25.16
Filing Date Shares Outstanding	51.93	51.44	45.77	45.45	44.78
Total Common Shares Outstanding	51.94	51.45	45.77	45.43	44.78
Working Capital	161.29	193.38	236.17	289.07	358.35
Book Value Per Share	3.39	4.39	5.38	6.79	8.02
Tangible Book Value	176.08	225.69	246.03	308.56	359.12
Tangible Book Value Per Share	3.39	4.39	5.38	6.79	8.02
Machinery	1.82	3.17	2.53	2.28	2.01
Leasehold Improvements	0.05	10.77	0.41	0.16	0.07

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q